Canadian Pharma, Biotech and Life Sciences Stocks

Is now the right time to invest in weed?

If there’s one group of people who can’t wait for 2019 to end, it’s cannabis investors. The ride they’ve been taken on over the last 12 months has been as nausea-inducing as any Canada Wonderland roller coaster, with stocks plummeting post-legalization in October 2018, rising again in March ...

Canopy Growth Corp’s corporate governance is terrible, this fund manager says

Want to know one big reason why Canopy Growth has faltered? Look at its corporate governance, says one investor. The news isn’t getting any better for Canada’s marijuana sector as a number of high-profile companies posted their earnings this week, including industry leader Canopy Growth (Canopy ...

Canopy Growth has price target slashed at PI Financial

Canadian licensed producer Canopy Growth (Canopy Growth Stock Quote, Chart, News NYSE:CGC) got a substantial price target cut from PI Financial’s Jason Zandberg this week, as the analyst reviewed the company’s latest quarterly results. In an update to clients on Thursday, Zandberg kept his “B ...

Liminal BioSciences is a “Hold”, says Echelon Wealth

After its latest quarterly numbers, Liminal BioSciences (Liminal BioSciences Stock Quote, Chart, News TSX:LMNL) is still a “Hold,” according to Echelon Wealth Partners analyst Douglas Loe, who reviewed the pharmaceutical company’s Q3 in an update to clients on Wednesday. Quebec-based Liminal ...

All is GUD with Knight Therapeutics, GMP says

All’s well with Knight Therapeutics (Knight Therapeutics Stock Quote, Chart, News TSX:GUD) after the specialty pharma company’s latest quarterly numbers, according to GMP Securities analyst Justin Keywood who reviewed the results in an update to clients on Wednesday. Shares of GUD dropped sharp ...

Centric Health will survive, Beacon Securities says

The road may have been bumpy lately for Centric Health (Centric Health Stock Quote, Chart, News TSX:CHH) but investors are likely to see better days ahead, according to Beacon Securities analyst Doug Cooper, who reviewed Centric’s latest quarterly results in an update to clients on Tuesday. Toron ...

Organigram has price target cut at Mackie Research

On the back of disappointing guidance from Canadian cannabis company Organigram Holdings (TSX:OGI), Mackie Research analyst Greg McLeish has lowered his price target for the stock from $8.50 to $7.50, saying in a client update on Tuesday that despite the setback OGI is poised to be one of the leadi ...

Q3 2019 Share Price Performance

Q3 2019 Share Price Performance Healthcare Stocks – Choppy Stalling Pattern Continues In this blog post, the Bloom Burton equity research team summarizes the performance of the Canadian healthcare sector during 3Q-2019, and provides commentary on select stock movements and overall market trends. ...

CRH Medical is set for a stellar 2020, Beacon Securities says

A volatile few years for CRH Medical Corporation (CRH Medical Corporation Stock Quote, Chart, News NASDAQ: CRHM) will culminate with a stellar 2020. So says Beacon Securities analyst Doug Cooper, who in a research update to clients today raised his target price on the stock from (US) $6.00 to $6.50 ...

Will Canopy Growth Corp win the pot sector’s game of Survivor?

As its peers drop by the wayside, is Canopy Growth Corp (Canopy Growth Corp Stock Quote, Chart, News TSX:WEED) destined to be the winner in the game of weed stock Survivor? Pot stocks across the board have been horrendous over the past half year, keeping investors at bay as they look for signs of p ...